Delving into the Latest Updates on Jiangsu Jiye Biopharmaceutical Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Jiangsu Jiye Biopharmaceutical Co., Ltd. is the production base of macromolecular biopharmaceuticals for Jiangxi Jemincare Group, and also the first industrialization base in the group's macromolecular biopharmaceutical field. It was established on September 18, 2020. The main products of the company's project are macromolecular biopharmaceuticals (monoclonal antibodies) and water injections, mainly used for the treatment of related diseases such as asthma, tumors, and specific dermatitis.

Disease Domain	Count

Infectious Diseases	1
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Monoclonal antibody	2
Biological products	1

Top 5 Target	Count

IgE(Immunoglobulin E)	1
LRRC32 x TGF-β1	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Approval

1

2

Phase 1 Clinical

Phase 2 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

JYB-1904 ( IgE )	Chronic Urticaria More	Phase 2
JMB-2004	Shock, Septic More	Phase 1
JYB-1907 ( LRRC32 x TGF-β1 )	Advanced Malignant Solid Neoplasm More	Phase 1
JYB-1931 ( MASP2 )	Glomerulonephritis, IGA More	IND Approval